<DOC>
	<DOC>NCT02568111</DOC>
	<brief_summary>The primary objective of this study is to evaluate the Injection Related Erythema (IRE) mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel (placebo). The secondary study objectives are to evaluate the IRE mitigation effect of a single administration of brimonidine tartrate in comparison with a vehicle gel on a more stringent definition scale, in accordance with the primary endpoint of the original brimonidine pivotal trials and participants' satisfaction with the overall appearance of their skin.</brief_summary>
	<brief_title>Brimonidine Tartrate for the Treatment of Injection Related Erythema</brief_title>
	<detailed_description>Participants naïve to treatment with subcutaneous (SC) interferons or oral Disease Modifying Therapy (DMT) who are about to start PLEGRIDY PEN therapy will be screened for participation in this Phase IV trial. Participants will remain on Plegridy therapy as prescribed by their physician. Plegridy will not be provided to participants by Biogen as a part of this study.</detailed_description>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<mesh_term>Erythema</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Interferon beta-1a</mesh_term>
	<mesh_term>Brimonidine Tartrate</mesh_term>
	<criteria>Key RRMS patients naïve to treatment with SC interferon or oral and/or IV DMT for which PLEGRIDY is deemed necessary by the treating physician. Patient willing and able to complete PSA and PAA questionnaires with minimal assistance. Key Known allergy to any interferon or any component of peginterferon beta1a. Patients with hypersensitivity to Brimonidine topical gel. Patients with other skin disorders. History of previous treatment with Brimonidine tartrate. NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>erythema</keyword>
	<keyword>PLEGRIDY</keyword>
	<keyword>injection site reaction (ISR)</keyword>
	<keyword>MS</keyword>
	<keyword>RRMS</keyword>
</DOC>